- |||||||||| mavrilimumab (KPL-301) / Kiniksa
mavrilimumab (Twitter) - May 15, 2022
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis. (Pubmed Central) - May 6, 2022
Rilonacept is a safe, once weekly, subcutaneously administered IL-1 "trap," indicated for the treatment of RP, and reduction in risk of recurrent pericarditis in adults and children ≥12 years of age.
- |||||||||| vixarelimab (RG6536) / Roche
Trial completion date, Trial primary completion date: KPL-716-C201: Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis (clinicaltrials.gov) - May 2, 2022
P2a/b, N=230, Recruiting,
Rilonacept is a safe, once weekly, subcutaneously administered IL-1 "trap," indicated for the treatment of RP, and reduction in risk of recurrent pericarditis in adults and children ≥12 years of age. Trial completion date: Mar 2023 --> Jul 2023 | Trial primary completion date: Feb 2022 --> Nov 2022
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis. (Pubmed Central) - Apr 29, 2022
Inflammasomes and the IL-1 pathways were found to be critical in its pathophysiology, leading to IL-1 inhibitors being developed. The high efficacy and safety of rilonacept for recurrent pericarditis means it could potentially be considered as a second-line therapy ahead of or as an alternative to corticosteroids, and highlight the great promise of targeted immunomodulatory therapy in this field.
- |||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: The inflammasome as a therapeutic target for myopericardial diseases. (Pubmed Central) - Apr 19, 2022
Anti-interleukin-1 (IL-1) agents (anakinra and rilonacept) appear to be a major advance in medical therapy of recurrent pericarditis and could be a therapeutic option also for myocarditis if confirmed in additional studies. In this review, we provide an update on the inflammasome as therapeutic target for myopericardial diseases, a significant advance in medical therapy for these diseases in the last five years.
- |||||||||| Review, Journal: Treatment of Giant Cell Arteritis (GCA). (Pubmed Central) - Apr 13, 2022
Despite this recent progress, the value, specific condition and optimal application of each treatment remain undecided. In this review, we discuss the scientific rationale for each treatment and the therapeutic strategy.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Rilonacept for the treatment of recurrent pericarditis. (Pubmed Central) - Apr 7, 2022
This anti-IL 1 agent has emerged as an efficacious treatment for RP, with potential use for glucocorticoid-free regimens and as monotherapy. Future trials are needed to explore these treatment options and to clarify the appropriate therapy duration.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Clinical, Review, Journal: Advances in pharmacotherapy for acute and recurrent pericarditis. (Pubmed Central) - Apr 7, 2022
Aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are first-line treatments for acute and recurrent pericarditis...Randomized clinical trials testing anakinra (a recombinant form of the IL-1 receptor antagonist blocking IL-1α and IL-1β) and rilonacept (an IL-1α and IL-1β trap) have shown that IL-1 blockade reduces recurrences...Patients with multiple recurrences and signs of pericardial and/or systemic inflammation might benefit from IL-1 blockers in order to interrupt cyclic flares of auto-inflammation. Given this evidence, guidelines should consider incorporating IL-1 blockers.
- |||||||||| Journal: Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications. (Pubmed Central) - Apr 5, 2022
In the following review, we provide a new perspective on the efficacy and safety of IL-1 inhibitors that have provided the novel results coming from recently published clinical trials. The present review article shows that IL-1β has a major role in the pathophysiology of cardiovascular disorders, its antagonists have beneficial effects in these conditions, and their use should be considered in future studies.
- |||||||||| Review, Journal: Interventions for reducing inflammation in familial Mediterranean fever. (Pubmed Central) - Apr 5, 2022
Based on the evidence, three times daily colchicine may reduce the number of people experiencing attacks, colchicine single dose and divided dose may not be different for children with FMF, canakinumab probably reduces the number of people experiencing attacks, and anakinra or canakinumab probably reduce CRP in colchicine-resistant participants; however, only a few RCTs contributed data for analysis. Further RCTs examining active interventions, not only colchicine, are necessary before a comprehensive conclusion regarding the efficacy and safety of interventions for reducing inflammation in FMF can be drawn.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review: Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. (Pubmed Central) - Mar 31, 2022
Importantly, recent findings showed how innate immunity plays a pivotal role in the pathogenesis of recurrent pericarditis with raised C-reactive protein, with inflammasome and IL-1 overproduction as drivers for systemic inflammatory response. In the era of tailored medicine, anti-IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflammatory phenotype.
- |||||||||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Advances in the Treatment of Giant Cell Arteritis. (Pubmed Central) - Mar 26, 2022
However, apart from the IL-6 pathway, there are other pro-inflammatory cytokines and growth factors involved in the typical intima hyperplasia and vascular remodeling of GCA. Among them, the more promising targets in GCA treatment are the IL12/IL23 axis antagonists, IL17 inhibitors, modulators of T lymphocytes, and inhibitors of either the JAK/STAT pathway, the granulocyte-macrophage colony-stimulating factor, or the endothelin, all of which are updated in this review.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Recurrent pericarditis: an update on diagnosis and management. (Pubmed Central) - Mar 23, 2022
Glucocorticoids are often used as second-line drugs, but they are associated with a high rate of recurrent events. Interleukin-1 inhibitors, such as anakinra and rilonacept, significantly reduce the risk of recurrences in patients with RP while on treatment.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
Review, Journal: Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review. (Pubmed Central) - Feb 24, 2022
However, in selected cases, after balancing for disease activity and risk of relapses, vaccination may be given seven days after the drug levels have returned to baseline, especially for IL-1 blocking agents with long half-lives such as canakinumab and rilonacept. This may help to ensure an ideal vaccine response in the face of the possibility that AIIRD patients may develop a more pronounced and severe COVID-19 disease course.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Clinical, Journal: Current treatment of recurrent pericarditis: safety considerations and future directions. (Pubmed Central) - Feb 19, 2022
The main distinction is between patients with an inflammatory phenotype (e.g. fever, elevation of markers of inflammation, pericardial and/or pleural effusion) vs. those without an inflammatory phenotype. Colchicine and anti IL-1 agents are especially efficacious and indicated for those with an inflammatory phenotype, while corticosteroids, azathioprine and immunoglobulins seem more indicated for those without evidence of systemic inflammation.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Recent advances in pericarditis. (Pubmed Central) - Feb 1, 2022
On the contrary, anti-IL-1 drugs are not indicated in patients with pericardial effusion whose cause is not attributable to inflammatory phenomena. Finally, many patients with RP are women of childbearing age, and the possibility for these women to become pregnant must be addressed by multidisciplinary teams.
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Arcalyst (rilonacept) / Regeneron, Kiniksa
INCESSANT PERICARDITIS AND CARDIAC TAMPONADE FOLLOWING THE BNT162B2 MRNA COVID-19 VACCINE (eAbstract site) - Jan 28, 2022 - Abstract #ACC2022ACC_2986;
In patients with incessant pericarditis, the use of rilonacept has been associated with marked reduction in recurrence. Rilonacept may serve as a therapeutic strategy for severe refractory cases of pericarditis secondary to mRNA vaccines.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Clinical, Journal: Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors. (Pubmed Central) - Jan 19, 2022
Although further studies are needed to refine therapeutic protocols and taper of concomitant therapies, IL-1 inhibitors, continue to consolidate as part of the pharmacological armamentarium to manage this complex condition with potential use as monotherapy. The aim of this review is to highlight the role of IL-1 pathway in RP and discuss the efficacy, safety, and clinical applicability of IL-1 inhibitors in the treatment of RP based on current evidence.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option. (Pubmed Central) - Jan 13, 2022
Additionally, new data indicate that rilonacept should be considered as an option for patients with recurrent pericarditis, as add-on therapy to colchicine and nonsteroidal anti-inflammatory drugs, in place of steroids. We review the current management options for recurrent pericarditis as well as rilonacept as a prospective new addition to our armamentarium.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Non-steroidal anti-inflammatory drugs for acute gout. (Pubmed Central) - Jan 7, 2022
Only low-certainty evidence was available for the comparisons NSAID versus rilonacept and NSAID versus acupuncture from single trials, or one NSAID versus another NSAID, which also included many NSAIDs that are no longer in clinical use. Although these data were insufficient to support firm conclusions, they do not conflict with clinical guideline recommendations based upon evidence from observational studies, findings for other inflammatory arthritis, and expert consensus, all of which support the use of NSAIDs for acute gout.
- |||||||||| mavrilimumab (KPL-301) / Kiniksa
Enrollment closed, Enrollment change: Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation (clinicaltrials.gov) - Jan 3, 2022
P2/3, N=815, Active, not recruiting,
Although these data were insufficient to support firm conclusions, they do not conflict with clinical guideline recommendations based upon evidence from observational studies, findings for other inflammatory arthritis, and expert consensus, all of which support the use of NSAIDs for acute gout. Recruiting --> Active, not recruiting | N=588 --> 815
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Review, Journal: The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. (Pubmed Central) - Dec 7, 2021
The paper also outlines the experiences gained during the repurposing of therapeutic molecules (hydroxychloroquine, ritonavir/ lopinavir, favipiravir, remdesivir, ivermectin, dexamethasone, camostatmesylate, and heparin), immunotherapeutic molecules (tocilizumab, mavrilimumab, baricitinib, and interferons), combination therapy, and convalescent plasma therapy to treat COVID-19 patients...The short-term repurposing of the existing drug may provide a successful outcome for COVID-19 patients. Therefore, more clinical trials can be initiated using potential anti-viral molecules by evaluating in different phases of clinical trials.
- |||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
Clinical, Review, Journal: IL-1β blockade in periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: case-based review. (Pubmed Central) - Nov 11, 2021
Anti-IL1 agents are used in colchicine-resistant cases of FMF...We conducted a literature search focusing on English articles with keywords including PFAPA, anakinra, canakinumab, and rilonacept...Failure of canakinumab to prevent PFAPA attacks in our case may arise from the differences in the pathophysiology of PFAPA and FMF. Thus, further experience with higher doses or shorter intervals of canakinumab is needed in children with PFAPA.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Recurrent pericarditis is less scary: the new therapeutic solutions. (Pubmed Central) - Oct 20, 2021
Other medically relevant therapeutic possibilities in refractory disease include azathioprine, methotrexate, and intravenous immunoglobulins. This brief review aims to summarize the treatment strategies of recurrent pericarditis in light of the most up-to-date evidence and recommendations.
- |||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
Clinical, Review, Journal: Clinical Trials in Pericardial Disease: New Paradigm Shift. (Pubmed Central) - Oct 12, 2021
This could translate into an upgraded recommendation for these agents in future guidelines. Treatment of pericardial diseases is improving moving towards a more personalized therapy according to the presentation and etiology, and new or old drugs could be important to expand the therapeutic spectrum.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Rilonacept (Arcalyst) for recurrent pericarditis. (Pubmed Central) - Oct 7, 2021
Treatment of pericardial diseases is improving moving towards a more personalized therapy according to the presentation and etiology, and new or old drugs could be important to expand the therapeutic spectrum. No abstract available
|
